Filed: 8/13/2024ACC: 0000950123-24-008225
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 9 equity positions with a total reported market value of $319.40M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
9
Positions
$319.40M
Total AUM (reported)
22.19M
Total Shares
Allocation by class
COMMON STOCK$258.03M80.8%
COMMON SHARES$61.37M19.2%
Portfolio Concentration
Top 3$220.31M69.0%
4–10$99.09M31.0%
Top 3 weight
69.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 22.19M
Sole
Full voting authority
22.19M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole9
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings9
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$129.51M
40.55%
Sole
2.35M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares1.05M
TypeSH
Market value$56.65M
17.74%
Sole
1.05M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$34.15M
10.69%
Sole
4.01M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$26.07M
8.16%
Sole
1.96M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares2.02M
TypeSH
Market value$23.60M
7.39%
Sole
2.02M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$21.86M
6.85%
Sole
6.53M
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$19.70M
6.17%
Sole
3.33M
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares500K
TypeSH
Market value$4.71M
1.48%
Sole
500K
Shared
0.00
None
0.00
KALA Bio, Inc.
SOLEShares443.66K
TypeSH
Market value$3.15M
0.98%
Sole
443.66K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $129.51M 40.55% | 2.35M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 1.05M | SH | $56.65M 17.74% | 1.05M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $34.15M 10.69% | 4.01M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $26.07M 8.16% | 1.96M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 2.02M | SH | $23.60M 7.39% | 2.02M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $21.86M 6.85% | 6.53M | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $19.70M 6.17% | 3.33M | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 500K | SH | $4.71M 1.48% | 500K | 0.00 | 0.00 |
KALA Bio, Inc.SOLE | Common Stock | 443.66K | SH | $3.15M 0.98% | 443.66K | 0.00 | 0.00 |